These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35962911)

  • 1. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
    Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
    BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
    Hair J; Maryon T; Lieneck C
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunities and challenges in biosimilar uptake in oncology.
    Dolan C
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
    Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
    Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.
    Barbier L; Vandenplas Y; Simoens S; Declerck P; Vulto AG; Huys I
    J Pharm Policy Pract; 2021 Jun; 14(1):53. PubMed ID: 34158128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey.
    Kolbe AR; Kearsley A; Merchant L; Temkin E; Patel A; Xu J; Jessup A
    BioDrugs; 2021 May; 35(3):363-372. PubMed ID: 33826078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
    Waterhouse DM; Ward P; Drosick DR; Burdette C; Davies D; Mendenhall MA
    JCO Oncol Pract; 2023 Nov; 19(11):1053-1057. PubMed ID: 37738533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
    Cisek S; Choi D; Stubbings J; Bhat S
    Am J Health Syst Pharm; 2023 Sep; 80(18):1223-1233. PubMed ID: 37257054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
    Hung A; Vu Q; Mostovoy L
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland.
    O'Callaghan J; Bermingham M; Leonard M; Hallinan F; Morris JM; Moore U; Griffin BT
    Regul Toxicol Pharmacol; 2017 Aug; 88():252-261. PubMed ID: 28666961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
    Dolinar R; Lavernia F; Edelman S
    Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provider and patient knowledge gaps on biosimilars: insights from surveys.
    Gibofsky A; Evans C; Strand V
    Am J Manag Care; 2022 Nov; 28(12 Suppl):S227-S233. PubMed ID: 36493396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.